At Jefferies in New York this June, Albert Bourla, CEO and chairman of Pfizer, piqued my interest. He said: “The way I see it ...
Three deals in the last week underscore a shift in pharma’s China partnering toward a wider range of therapies — and ...
The Trump administration’s GLOBE model has shriveled, and in the process, the threat it poses to biomedical innovation has ...
YolTech has evidence that rebuts Beam’s accusations that it misappropriated trade secrets, Emma Wang, the scientist who is ...
Revier is targeting class IIa histone deacetylases (HDACs), whose enzymatic activity is mostly dormant in healthy cells but ...
Aging biology, women's health, sleep, mitochondrial health, inflammation, and prevention-oriented ...
The fate of uniQure’s Huntington disease gene therapy is once again in the balance, with four-year data raising fresh ...
Merck and Daiichi Sankyo withdrew their BLA for ifinatamab deruxtecan two weeks before its PDUFA date. The partners were ...
• IgA nephropathy drug development — Seven global approvals in five years, validated biomarkers, and FDA flexibility have ...
Months after reported negotiations fell off between Merck and Revolution Medicines, the pharma has instead entered a licensing deal with China-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results